Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 1;29(1):14-21.
doi: 10.4078/jrd.2022.29.1.14.

Juvenile Dermatomyositis

Jung Woo Rhim  1
Affiliations
Review

Juvenile Dermatomyositis

Jung Woo Rhim. J Rheum Dis. .

Abstract

Juvenile dermatomyositis (JDM) is a systemic capillary vasculopathy. Patients present with proximal muscle weakness, raised muscle enzymes, and pathognomic skin rashes such as heliotrope rash, Gottron's papules. Main complications are calcinosis, lipodystrophy, osteoporosis. Complement-mediated damage of vessels is a major mechanism. Magnetic resonance imaging is currently widely used to diagnosis of JDM. The goals of treatment are to control inflammatory myositis and prevent disease complication. Early, aggressive treatment of JDM associated with a better prognosis. High-dose corticosteroids in combination with methotrexate is the mainstay of treatment. The course of JDM is variable.

Keywords: Juvenile dermatomyositis; Muscle weakness; Rash.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST No potential conflict of interest relevant to this article was reported.

Figures

Figure 1
Figure 1
Classification tree for subgroups of idiopathic inflammatory myopathies (IIM). PM: polymyositis, IBM: inclusion body myositis, ADM: amyopathic dermatomyositis, DM: dermatomyositis, JDM: juvenile dermatomyositis, EULAR/ACR: European League Against Rheumatism/American College of Rheumatology. *The PM subset includes immune-mediated necrotizing myopathies (IMNM).
See this image and copyright information in PMC

References

    1. Mathiesen PR, Zak M, Herlin T, Nielsen SM. Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients. Clin Exp Rheumatol. 2010;28:782–9. - PubMed
    1. Robinson AB, Hoeltzel MF, Wahezi DM, Becker ML, Kessler EA, Schmeling H, et al. Clinical characteristics of children with juvenile dermatomyositis: the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care Res (Hoboken) 2014;66:404–10. doi: 10.1002/acr.22142. - DOI - PMC - PubMed
    1. Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 2003;49:300–5. doi: 10.1002/art.11122. - DOI - PubMed
    1. Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol. 1995;34:732–6. doi: 10.1093/rheumatology/34.8.732. - DOI - PubMed
    1. Mamyrova G, O'Hanlon TP, Monroe JB, Carrick DM, Malley JD, Adams S, et al. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum. 2006;54:3979–87. doi: 10.1002/art.22216. - DOI - PMC - PubMed

LinkOut - more resources